SCHEMBL6554618

SCHEMBL6554618

CCCCCCOC(=O)NC(=N)c1ccc(O)c(CNC(=O)c2ccc(C(=O)N3CCCC3)c(C)c2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
HPGD P15428 3/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
SMPD1 P17405 2/20 0.36
ESR1 P03372 1/20 0.34
PPARD Q03181 2/20 0.34
OPRM1 P35372 1/20 0.34
OPRD1 P41143 1/20 0.34
MASP2 O00187 1/20 0.33
CNR1 P21554 1/20 0.33
HSP90AA1 P07900 1/20 0.33
HSP90AB1 P08238 1/20 0.33
TLR2 O60603 1/20 0.33
MAPT P10636 1/20 0.33
THRA P10827 1/20 0.33
THRB P10828 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5094300 0.86 ALDH1A1 (0.41) ALDH1A1HPGDLMNAHTTMEN1
SCHEMBL6555885 0.82 HPGD (0.43) ALDH1A1HPGDLMNAHTTKMT2A
SCHEMBL6554900 0.81 CACNA1B (0.41) ALDH1A1HPGDLMNAHTTMEN1
Hydrochloric Acid SCHEMBL6555794 0.81 HPGD (0.43) ALDH1A1HPGDLMNAHTTKMT2A
SCHEMBL2997517 0.79 F10 (0.45) ALDH1A1HPGDLMNAHTT
SCHEMBL5094271 0.79 MEN1 (0.41) ALDH1A1HPGDHTTMEN1KMT2A
Hydrochloric Acid SCHEMBL6554962 0.78 F10 (0.44) ALDH1A1HPGDLMNAHTT
SCHEMBL6556709 0.77 ALDH1A1 (0.39) ALDH1A1LMNAMEN1KMT2ASMPD1
SCHEMBL6325719 0.76 CNR1 (0.47) ALDH1A1HPGDLMNAHTTMEN1
SCHEMBL6329449 0.76 CNR1 (0.43) ALDH1A1HPGDLMNAHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020151534-A1 Antithrombotic compounds BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-10-17 US claimed
EP-1390357-A2 ANTI-THROMBOTIC COMPOUNDS, PRODUCTION AND USE THEREOF AS MEDICAMENTS Boehringer Ingelheim Pharma GmbH & Co. KG (DE) 2004-02-25 EP disclosed
US-20020151534-A1 Antithrombotic compounds BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-10-17 US disclosed
WO-2002062778-A2 ANTI-THROMBOTIC COMPOUNDS, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020151534-A1 Antithrombotic compounds SERPINC1, PF4, F2 ALDH1A1 192/4885HPGD 569/4885LMNA 1677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.